<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Human papillomavirus 9-valent vaccine (9vHPV): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Human papillomavirus 9-valent vaccine (9vHPV): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Human papillomavirus 9-valent vaccine (9vHPV): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="98758" href="/d/html/98758.html" rel="external">see "Human papillomavirus 9-valent vaccine (9vHPV): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="101845" href="/d/html/101845.html" rel="external">see "Human papillomavirus 9-valent vaccine (9vHPV): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26639611"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gardasil 9</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56454983"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Gardasil 9</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26619130"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Viral)</li></ul></div>
<div class="block doa drugH1Div" id="F26869443"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;">
<b>Note:</b> Consult CDC/Advisory Committee on Immunization Practices (ACIP) annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2023]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dedd7ff3-b860-4044-a1c5-28d0290fe43d">Immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immunization: IM:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer's labeling: Adults ≤45 years of age: 3-dose series: 0.5 mL at 0, 2, and 6 months.</p>
<p style="text-indent:-2em;margin-left:2em;">CDC/ACIP recommended immunization schedule: Adults ≤26 years of age: Catch-up vaccination is recommended in all persons ≤26 years of age if not previously vaccinated or have not completed the 3-dose series (typically administer first dose at age 11 to 12 years). Second and third doses may be given after age 26 years to complete a previously initiated series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25167164','lexi-content-ref-27977643','lexi-content-ref-31415491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25167164','lexi-content-ref-27977643','lexi-content-ref-31415491'])">Ref</a></span>). <b>Note:</b> Shared clinical decision-making regarding catch-up human papillomavirus vaccination is recommended for some adults 27 to 45 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31415491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31415491'])">Ref</a></span>). The American Cancer Society does not endorse vaccination in adults 27 to 45 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32639044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32639044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Have not received any doses</i>: 3-dose series: IM: 0.5 mL at 0, 1 to 2, and 6 months. There should be a 4-week minimum interval between the first and second dose; a 12-week minimum interval between the second and third dose; a 5-month minimum interval between the first and third dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Partially vaccinated, first dose before 15 years of age</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">If 2 doses administered at least 5 months apart: No more doses needed.</p>
<p style="text-indent:-2em;margin-left:6em;">If only a single dose or if doses &lt;5 months apart: <b>IM:</b> Administer one additional 0.5 mL dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Partially vaccinated, first dose at 15 years of age or later</i>: Complete 3-dose series: <b>IM:</b> There should be a 4-week minimum interval between the first and second dose; a 12-week minimum interval between the second and third dose; a 5-month minimum interval between the first and third dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990573"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987928"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dop drugH1Div" id="F26869442"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="101845" href="/d/html/101845.html" rel="external">see "Human papillomavirus 9-valent vaccine (9vHPV): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACIP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACIP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b> Children ≥9 years and Adolescents: IM: 0.5 mL per dose for 2 or 3 doses; see the following recommendations for number and timing of doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27977643','lexi-content-ref-25811679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27977643','lexi-content-ref-25811679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CDC/ACIP recommended immunization schedule: Routine vaccination at 11 to 12 years of age for all persons; may start as early as 9 years of age. AAP and ACS recommend routine vaccination between 9 and 12 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32639044','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32639044','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">In a 2-dose schedule, minimum interval between first and second doses is 5 months.</p>
<p style="text-indent:-2em;margin-left:6em;">In a 3-dose schedule, minimum interval between first and second doses is 4 weeks; the minimum interval between the second and third dose is 12 weeks; the minimum interval between first and third doses is 5 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27977643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27977643'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non-immunocompromised patients and certain specified medical conditions</i>: Asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, central nervous system, anatomic barrier defects (eg, cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents &lt;15 years: <i>2-dose series</i>: IM: 0.5 mL at 0, and 6 to 12 months. Administer first dose at age 11 to 12 years. For patients with any history of sexual abuse or assault, vaccination should be started at 9 years.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥15 years: <i>3-dose series</i>: IM: 0.5 mL at 0, 1 to 2, and 6 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompromised patients: </i>Including those with conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, or immunosuppressive therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: <i>3-dose series</i>: IM: 0.5 mL at 0, 1 to 2, and 6 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturing labeling: May not reflect current practice:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥9 years and Adolescents &lt;15 years:</p>
<p style="text-indent:-2em;margin-left:8em;">2-dose series: IM: 0.5 mL per dose; administer the second dose at 6 to 12 months after initial dose. If the second dose is inadvertently administered earlier than 5 months after the first dose, then patient should be converted to a 3-dose series.</p>
<p style="text-indent:-2em;margin-left:8em;">3-dose series: IM: 0.5 mL per dose; administer the second and third doses at 2 and 6 months after initial dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥15 years: IM: 0.5 mL per dose for a total of 3 doses; administer the second and third doses at 2 and 6 months after initial dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization:</b> CDC/ACIP recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27977643','lexi-content-ref-31415491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27977643','lexi-content-ref-31415491'])">Ref</a></span>): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number. Children ≥9 years and Adolescents: IM: 0.5 mL per dose for a total of 2 to 3 doses (See CDC/ACIP recommendations in <b>Primary Immunization</b> for 2-dose vs 3-dose schedule criteria):</p>
<p style="text-indent:-2em;margin-left:4em;">First dose given on the elected date.</p>
<p style="text-indent:-2em;margin-left:4em;">Second dose given at least 4 weeks after the first dose (for a 3-dose schedule) or 5 months after the first dose (for a 2-dose schedule).</p>
<p style="text-indent:-2em;margin-left:4em;">Third dose (for a 3-dose schedule) given at least 12 weeks after the second dose and at least 5 months after the first dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51151978"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51151979"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F27368404"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Reported incidences are for females 9 to 45 years of age and males 9 to 26 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (7% to 42%; increased with successive doses), pain at injection site (63% to 90%), swelling at injection site (13% to 49%; increased with successive doses)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (7% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site pruritus (1% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (≤1%), nausea (1% to 4%), upper abdominal pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Autoimmune disease (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site (1%), bruising at injection site (2%), hematoma at injection site ( ≤5%), hypersensitivity reaction at injection site (1%), induration at injection site (≤2%), injection site nodule (1%), injection site reaction (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤3%), fatigue (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal pain (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Warm sensation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Status asthmaticus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting</p></div>
<div class="block coi drugH1Div" id="F26619132"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of this vaccine or human papillomavirus (types 6, 11, 16, 18) vaccine (recombinant).</p></div>
<div class="block war drugH1Div" id="F26869399"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinitis) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Human papillomavirus infection: There is no evidence that individuals already infected with human papillomavirus (HPV) will be protected; those already infected with 1 or more HPV types were protected from disease caused by the remaining HPV types. Not for the treatment of active disease; will not protect against diseases not caused by HPV vaccine types not included in the vaccine. Does not eliminate the necessity for recommended cervical or anal cancer screenings.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i> Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Previously vaccinated with Gardasil (quadrivalent): Safety and immunogenicity of Gardasil 9 were assessed in individuals who previously completed a 3-dose vaccination series with Gardasil (quadrivalent). Studies using a mixed regimen of HPV vaccines to assess interchangeability were not performed. Per the ACIP, if the provider does not have available or does not know the HPV product used previously, any gender appropriate product can be used to complete the series (CDC/ACIP [Petrosky 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Yeast: Product may contain yeast.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]). Vaccination is safe for individuals 27 to 45 years of age; however, consider decreased effectiveness and potential for lower cancer prevention in these older ages (ACS [Saslow 2020]; CDC/ACIP [Meites 2019])).</p>
<p style="text-indent:-2em;margin-left:4em;">• Maximum efficacy: The entire series should be completed for maximum efficacy.</p></div>
<div class="block foc drugH1Div" id="F26639612"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gardasil 9:  (0.5 mL) [contains polysorbate 80, yeast extract]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gardasil 9:  (0.5 mL) [contains polysorbate 80, yeast extract]</p></div>
<div class="block geq drugH1Div" id="F26639610"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F56454984"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Gardasil 9: (0.5 mL) [contains polysorbate 80, yeast extract; latex-free]</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension Prefilled Syringe, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Gardasil 9: (0.5 mL) [contains polysorbate 80, yeast extract; latex-free]</p></div>
<div class="block adm drugH1Div" id="F26869447"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM:</b> Shake suspension well before use. Do not use if discolored or if contains particulate matter, or if syringe is cracked. Inject the entire dose IM into the deltoid region of the upper arm or higher anterolateral thigh area. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACIP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACIP.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (≤23-gauge) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACIP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACIP.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614576"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM: Shake suspension well before use. Do not use if discolored or if contains particulate matter, or if syringe is cracked. Inject the entire dose IM into the deltoid region of the upper arm or higher anterolateral thigh area. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACIP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACIP.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACIP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACIP.1'])">Ref</a></span>).</p></div>
<div class="block meg drugH1Div" id="F46561285"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;margin-left:0em;display:inline">In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fhpv-gardasil-9.html&amp;token=W2kSAaOjZU9MrMfHTzJjF6NZqGSoVD7pMAn8fa6fl4H2eneL34e9lv8f%2BihizQSjDrWkISN625XMMACQdiYZSQpjG1R8MtCJfLTzLcmf5O0%3D&amp;TOPIC_ID=98713" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv-gardasil-9.html</a></p></div>
<div class="block use drugH1Div" id="F26619125"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of human papillomavirus infection:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Females 9 to 45 years of age:</p>
<p style="text-indent:-2em;margin-left:4em;">For the prevention of the following diseases:</p>
<p style="text-indent:-2em;margin-left:6em;">Cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58.</p>
<p style="text-indent:-2em;margin-left:6em;">Genital warts (condyloma acuminata) caused by HPV types 6 and 11.</p>
<p style="text-indent:-2em;margin-left:4em;">For the prevention of the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:</p>
<p style="text-indent:-2em;margin-left:6em;">Cervical intraepithelial neoplasia grades 1, 2, and 3.</p>
<p style="text-indent:-2em;margin-left:6em;">Cervical adenocarcinoma in situ.</p>
<p style="text-indent:-2em;margin-left:6em;">Vulvar intraepithelial neoplasia grades 2 and 3.</p>
<p style="text-indent:-2em;margin-left:6em;">Vaginal intraepithelial neoplasia grades 2 and 3.</p>
<p style="text-indent:-2em;margin-left:6em;">Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.</p>
<p style="text-indent:-2em;margin-left:2em;">Males 9 through 45 years of age:</p>
<p style="text-indent:-2em;margin-left:4em;">For the prevention of the following diseases:</p>
<p style="text-indent:-2em;margin-left:6em;">Anal, oropharyngeal, and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.</p>
<p style="text-indent:-2em;margin-left:6em;">Genital warts (condyloma acuminata) caused by HPV types 6 and 11.</p>
<p style="text-indent:-2em;margin-left:4em;">For the prevention of the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:</p>
<p style="text-indent:-2em;margin-left:6em;">AIN grades 1, 2, and 3.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females and males 11 to 12 years of age; for patients with any history of sexual abuse or assault, vaccination should be started at 9 years of age. Catch-up vaccination is recommended for all persons through 26 years of age. Shared clinical decision-making regarding catch-up HPV vaccination is recommended for some adults 27 to 45 years of age (CDC/ACIP [Meites 2019]). The American Academy of Pediatrics and the American Cancer Society (ACS) recommend routine vaccination for individuals 9 to 12 years of age (ACS [Saslow 2020]; <i>Red Book</i> [AAP 2018]). ACS recommends catch-up vaccination only for individuals through 26 years of age (ACS [Saslow 2020]).</p></div>
<div class="block mst drugH1Div" id="F26619129"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Papillomavirus vaccine 9-valent (Gardasil 9) may be confused with Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil)</p>
<p style="text-indent:-2em;margin-left:4em;">HPV (human papilloma virus vaccine, 9vHPV is the correct abbreviation) may be confused with IPV (inactivated poliovirus vaccine)</p>
<p style="text-indent:-2em;margin-left:4em;">HPV (human papilloma virus vaccine, 9vHPV is the correct abbreviation) may be confused with HBV (previously used for hepatitis B vaccine; HepB is correct abbreviation)</p>
<p style="text-indent:-2em;margin-left:4em;">HPV (human papilloma virus vaccine, 9vHPV is the correct abbreviation) may be confused with Hib (<i>Haemophilus</i> b conjugate vaccine)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26639798"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F26639795"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49309069"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy testing is not required prior to administration of the vaccine (ACOG 2020; CDC/ACIP [Petrosky 2015]).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, the human papillomavirus vaccine is not expected to decrease female fertility (Christianson 2020; Schmuhl 2020). However, human papillomavirus infection may be associated with infertility in males and females. Vaccination may increase fertility in some patients; however, additional study is needed (Garolla 2018; McInerney 2017; Pereira 2015).</p></div>
<div class="block pri drugH1Div" id="F26869396"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on available data, an increased risk of adverse pregnancy outcomes, specifically miscarriage or congenital anomalies, has not been observed following inadvertent administration of the papillomavirus vaccine during pregnancy (ACOG 2020; Kharbanda 2021; Landazabal 2019). However, administration of the vaccine in pregnancy is not recommended. The vaccine series (or completion of the series) should be delayed until pregnancy is completed (ACOG 2020; CDC/ACIP [Petrosky 2015]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to the papillomavirus (9-valent) vaccine is ongoing. A registry has been established for patients exposed to the Gardasil 9 HPV vaccine during pregnancy (1-800-986-8999).</p></div>
<div class="block brc drugH1Div" id="F26869398"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if components of this vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during following immunization should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. However, maternal vaccination is not a contraindication to breastfeeding; the papillomavirus vaccine may be administered to breastfeeding patients (ACIP [Kroger 2023]; ACOG 2020). Nonlive vaccines have not been shown to affect the safety of the breastfed infant or mother (ACIP [Kroger 2023]).</p></div>
<div class="block mop drugH1Div" id="F26869481"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Screening for human papillomavirus is not required prior to vaccination. Monitor for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. Continue recommended anal cancer screening.</p>
<p style="text-indent:0em;margin-top:2em;">Females: Gynecologic screening exam, papillomavirus test; screening for cervical cancer should continue per current guidelines following vaccination.</p></div>
<div class="block pha drugH1Div" id="F26869404"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Contains inactive human papillomavirus (HPV) proteins (types 6 L1,11 L1, 16 L1, 18 L1, 31 L1, 33 L1, 45 L1, 52 L1, and 58 L1) which produce neutralizing antibodies to prevent cervical, vulvar, vaginal, and anal  cancers, cervical adenocarcinoma, cervical, vaginal, vulvar, and anal neoplasia, and genital warts caused by HPV. Efficacy of HPV 9-valent vaccine against anogenital diseases related to the vaccine HPV types in humans is thought to be mediated by humoral immune responses induced by the vaccine, although the exact mechanism of protection is unknown.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F48851701"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gardasil 9</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32732766">
<a name="32732766"></a>American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. <i>Obstet Gynecol</i>. 2020;136(2):e15-e21. doi:10.1097/AOG.0000000000004000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/32732766/pubmed" id="32732766" target="_blank">32732766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479634">
<a name="31479634"></a>Christianson MS, Wodi P, Talaat K, Halsey N. Primary ovarian insufficiency and human papilloma virus vaccines: a review of the current evidence. <i>Am J Obstet Gynecol</i>. 2020;222(3):239-244. doi:10.1016/j.ajog.2019.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/31479634/pubmed" id="31479634" target="_blank">31479634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19684472">
<a name="19684472"></a>Einstein MH, Baron M, Levin MJ, et al; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. <i>Hum Vaccin</i>. 2009;5(10):705-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/19684472/pubmed" id="19684472" target="_blank">19684472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gardasil 9 (human papilloma virus 9-valent vaccine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gardasil.2">
<a name="Gardasil.2"></a>Gardasil 9 (human papilloma virus 9-valent vaccine) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29343824">
<a name="29343824"></a>Garolla A, De Toni L, Bottacin A, et al. Human papillomavirus prophylactic vaccination improves reproductive outcome in infertile patients with HPV semen infection: a retrospective study. <i>Sci Rep</i>. 2018;8(1):912. doi:10.1038/s41598-018-19369-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/29343824/pubmed" id="29343824" target="_blank">29343824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33818618">
<a name="33818618"></a>Kharbanda EO, Vazquez-Benitez G, DeSilva MB, et al. Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes. <i>JAMA Netw Open</i>. 2021;4(4):e214340. doi:10.1001/jamanetworkopen.2021.4340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/33818618/pubmed" id="33818618" target="_blank">33818618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACIP.1">
<a name="ACIP.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated 2023. Accessed April 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660400">
<a name="30660400"></a>Landazabal CS, Moro PL, Lewis P, Omer SB. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. <i>Vaccine</i>. 2019;37(9):1229-1234. doi:10.1016/j.vaccine.2018.11.077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/30660400/pubmed" id="30660400" target="_blank">30660400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25167164">
<a name="25167164"></a>Markowitz LE, Dunne EF, Saraiya M, et al; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Recomm Rep</i>. 2014;63(49):1182]. <i>MMWR Recomm Rep</i>. 2014;63(RR-05):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/25167164/pubmed" id="25167164" target="_blank">25167164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28881394">
<a name="28881394"></a>McInerney KA, Hatch EE, Wesselink AK, et al. The effect of vaccination against human papillomavirus on fecundability. <i>Paediatr Perinat Epidemiol</i>. 2017;31(6):531-536. doi:10.1111/ppe.12408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/28881394/pubmed" id="28881394" target="_blank">28881394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27977643">
<a name="27977643"></a>Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination – updated recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep.</i> 2016;65(49):1405-1408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/27977643/pubmed" id="27977643" target="_blank">27977643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31415491">
<a name="31415491"></a>Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2019;68(32):698-702. doi: 10.15585/mmwr.mm6832a3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/31415491/pubmed" id="31415491" target="_blank">31415491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26609434">
<a name="26609434"></a>Pereira N, Kucharczyk KM, Estes JL, et al. Human papillomavirus infection, infertility, and assisted reproductive outcomes. <i>J Pathog</i>. 2015;2015:578423. doi:10.1155/2015/578423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/26609434/pubmed" id="26609434" target="_blank">26609434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25811679">
<a name="25811679"></a>Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):300-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/25811679/pubmed" id="25811679" target="_blank">25811679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32639044">
<a name="32639044"></a>Saslow D, Andrews KS, Manassaram-Baptiste D, Smith RA, Fontham ETH; American Cancer Society Guideline Development Group. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. <i>CA Cancer J Clin</i>. 2020;70(4):274-280. doi:10.3322/caac.21616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/32639044/pubmed" id="32639044" target="_blank">32639044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32253100">
<a name="32253100"></a>Schmuhl NB, Mooney KE, Zhang X, Cooney LG, Conway JH, LoConte NK. No association between HPV vaccination and infertility in U.S. females 18-33 years old. <i>Vaccine</i>. 2020;38(24):4038-4043. doi:10.1016/j.vaccine.2020.03.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/32253100/pubmed" id="32253100" target="_blank">32253100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-9vhpv-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 98713 Version 134.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
